首页|拉米夫定联合阿德福韦酯对失代偿期乙型肝炎肝硬化患者的疗效评价

拉米夫定联合阿德福韦酯对失代偿期乙型肝炎肝硬化患者的疗效评价

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
目的 探讨拉米夫定联合阿德福韦酯治疗对失代偿期乙型肝炎肝硬化患者的疗效评价.方法 将2013年8月~2015年6月临安市人民医院消化内科收治的90例失代偿期乙型肝炎肝硬化患者作为本次研究对象,按照随机数表方法分为观察组和对照组,每组各45例,总的疗程均为1年.观察组采用拉米夫定联合阿德福韦酯治疗,对照组采用拉米夫定治疗.比较治疗后2组患者临床疗效、治疗前后肝功能的指标、HBV-DNA变化与Child-pugh评分.结果 治疗后,观察组的总有效率(93.33%)明显高于对照组(48.89%),差异有统计学意义(P<0.05);治疗后,观察组的丙氨酸转氨酸、总胆红素、天冬氨酸转氨酶(71.23±21.32)U/L、(28.32±4.65)μmol/lL、(32.25±9.25)U/L)显著低于对照组(111.54±16.25)U/L、(46.53±4.89)μmol/lL、(45.56±12.11)U/L,观察组的白蛋白(39.82±2.62)g/L明显高于对照组(35.55±2.22)g/L,差异有统计学意义(P<0.05);治疗后,观察组的乙型肝炎HBV-DNA水平、Dhild-pugh评分(2.78±0.45)log10 copies/mL、(6.12±1.23)分明显低于对照组(3.89±0.65)log10 copies/mL、(7.89±1.21)分,差异有统计学意义(P<0.05).结论 拉米夫定联合阿德福韦酯对失代偿期乙型肝炎肝硬化疗效显著,可有效的改善患者的肝功能、Dhild-pugh评分、HBV-DNA水平.
Effect of lamivudine combined with adefovir ester of hepatitis B cirrhosis of the liver decompensation period curative effect evaluation
Objective To evaluate the efficacy of lamivudine and adefovir in the treatment of patients with decompensated hepatitis B cirrhosis . Methods 90 cases of patients with hepatitis B cirrhosis of the liver decompensation period from August 2013 to June 2015 in our hospital were researched.According to the random number table method divided into observation group and control group , each of 45 cases, the total course of treatment was one year.The observation group was treated with lamivudine combined with adefovir dipivoxil , control group was treated with lamivudine.The clinical effect, the indexes of liver function, the changes of HBV-DNA and Child-pugh score were compared between the two groups after treatment.Results After treatment, the total effective rate of the observation group ( 93.33%) was obviously higher than that of control group (48.89%), the difference was statistically significant (P<0.05), the observation group alanine amino acid, total bilirubin, aspartate aminotransferase were (71.23 ±21.32)U/L, (28.32 ±4.65)Umol/lL, (4.65 ±9.25)U/L, they were significantly lower than control group (111.54 ±16.25)U/L, (46.53 ±4.89 ) Umol/L, ( 4.89 ±12.11 ) U/L, the observation group albumin ( 39.82 ±2.62 ) g/L was significantly higher than control group (35.55 ±2.22)g/L, the difference was statistically significant (P<0.05), after treatment, the observation group hepatitis b HBV DNA levels, Dhild pugh score (2.78 ±0.45)log10 copies/mL, (6.12 ±1.23) were significantly lower than the control group (3.89 ±0.65)log10 copies/mL, (7.89 ± 1.21)scores, the difference was statistically significant (P <0.05).Conclusion The combination of lamivudine and adefovir dipivoxil significantly decompensated hepatitis B cirrhosis has a curative effect, it could effectively improve the patient's liver function, Dhild-pugh score, HBV-DNA level.

lamivudineadefovir estercombinehepatitis bcirrhosis of the liver

方亚平、赵亚莹、潘红莲

展开 >

浙江省临安市人民医院 消化内科,浙江 临安 300311

浙江省临安市人民医院 病理科,浙江 临安 300311

拉米夫定 阿德福韦酯 联合 乙型肝炎 肝硬化

2017

10.3969/j.issn.1005-1678.2017.02.052

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN：1005-1678
年,卷(期)：2017.37(2)
  • 12
  • 12